TNF secures investment, CRO services from Prevail Partners
TNF Pharmaceuticals has hired contractor Prevail InfoWorks to run a Phase II trial of MYMD-1 in sarcopenia, also known as age-related muscle loss.
The contract will also see the CRO’s parent company, healthcare-focused investment firm Prevail Partners, purchase 283,019 shares of TNF common stock at $2.12 per share.
In a press statement, TNF chief medical officer Mitchell Glass said, “The fund’s investment in TNF points to their confidence in our potent oral synthetic TNF-alpha inhibitor MYMD-1’s potential to transform how TNFα-based diseases are treated.
“Our study will benefit from their unique experience and expertise. We are excited about our new partners and our close alignment of interests in executing our upcoming clinical studies efficiently and effectively.”
MYMD-1 is an oral drug designed to treat multiple conditions related to immune-metabolic dysregulation. It blocks the activity of excess TNFα, which supports the restoration of control and regulation of the immune system, according to TNF.
An earlier Phase II study evaluating the safety and efficacy of MYMD-1 as a treatment for sarcopenia was completed in 2023 by the Clinical Research of West Florida.
According to TNF – which used to be known as MyMD Pharmaceuticals - the earlier study achieved statistically significant positive results and met the primary endpoints for reducing chronic inflammatory markers.
News of the agreement with TNF comes just weeks after Prevail Partners signed a similar investment and clinical trial services deal with Kairos Pharma.
Under the agreement, Prevail participated in Kairos’ initial public offering when it listed on the New York Stock Exchange.
The deal also saw Prevail InfoWorks agree to provide analytics, site management, monitoring, and pharmacovigilance services for two studies of Kairos’ lead candidate, ENV105, which is being developed to treat various types of cancer.
DepositPhotos/Olivier26